Abstract
Background. New aerosol drugs for infants may require more efficient delivery systems, including face masks. Maximizing delivery efficiency requires tight-fitting masks with minimal internal mask volumes, which could cause carbon dioxide (CO2) retention. An RNA-interference-based antiviral for treatment of respiratory syncytial virus in populations that may include young children is designed for aerosol administration. CO2 accumulation within inhalation face masks has not been evaluated. Methods. We simulated airflow and CO2 concentrations accumulating over time within a new facemask designed for infants and young children (PARI SMARTMASK® Baby). A one-dimensional model was first examined, followed by 3-dimensional unsteady computational fluid dynamics analyses. Normal infant breathing patterns and respiratory distress were simulated. Results. The maximum average modeled CO2 concentration within the mask reached steady state (3.2% and 3% for normal and distressed breathing patterns resp.) after approximately the 5th respiratory cycle. After steady state, the mean CO2 concentration inspired into the nostril was 2.24% and 2.26% for normal and distressed breathing patterns, respectively. Conclusion. The mask is predicted to cause minimal CO2 retention and rebreathing. Infants with normal and distressed breathing should tolerate the mask intermittently delivering aerosols over brief time frames.
Highlights
New aerosol drugs may require more efficient delivery systems, but devices to safely and effectively deliver aerosols to young children have been insufficiently evaluated
We simulated airflow and CO2 concentrations accumulating over time within a new facemask designed for infants and young children (PARI SMARTMASK Baby)
A tight-fitting mask may increase the possibility of CO2 retention and rebreathing of exhaled air by the patient unless specific design considerations are sought to combat the problem
Summary
New aerosol drugs may require more efficient delivery systems, but devices to safely and effectively deliver aerosols to young children have been insufficiently evaluated. Because very young infants are obligate nose breathers, they cannot receive aerosols via a mouthpiece and require a facemask. Both the contour of the mask [1] and the seal between the mask and the patient’s face affect aerosol delivery. New aerosol drugs for infants may require more efficient delivery systems, including face masks. We simulated airflow and CO2 concentrations accumulating over time within a new facemask designed for infants and young children (PARI SMARTMASK Baby). The maximum average modeled CO2 concentration within the mask reached steady state (3.2% and 3% for normal and distressed breathing patterns resp.) after approximately the 5th respiratory cycle. Infants with normal and distressed breathing should tolerate the mask intermittently delivering aerosols over brief time frames
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have